CG Oncology Reports Strong Cash Position, Significant ATM Sales, and Favorable Legal Outcome in Annual Report

summarizeSummary

CG Oncology's 2025 annual report reveals a strong cash balance of $930.2 million, including $188.0 million from recent ATM sales, and a favorable legal verdict that eliminates a potential 5% royalty on future product sales.

check_boxKey Events

• Strong Cash Position and Recent Capital Raise

  The company reported $742.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025. This was further augmented by $188.0 million in net proceeds from at-the-market (ATM) equity sales of 3,623,101 shares at a weighted-average price of $52.96 per share, occurring subsequent to year-end through February 27, 2026, bringing the total available cash to approximately $930.2 million. This substantial capital infusion provides a runway of at least 12 months and was executed while the stock is trading near its 52-week high.

• Favorable Legal Outcome in Royalty Dispute

  The company announced a significant legal victory against ANI Pharmaceuticals, Inc. A Superior Court granted summary judgment in CG Oncology's favor regarding a potential 5% royalty on cretostimogene sales, and a jury unanimously rejected ANI's unjust enrichment claims. This outcome removes a material financial burden on future product revenues, although ANI is expected to pursue appeals.

• Advancing Clinical Pipeline and Regulatory Milestones

  CG Oncology confirmed the initiation of its Biologics License Application (BLA) submission for cretostimogene in high-risk BCG-unresponsive NMIBC (BOND-003 Cohort C) in Q4 2025, with completion expected in 2026. The company also reiterated the expedited timeline for topline data from its Phase 3 PIVOT-006 trial in intermediate-risk NMIBC, now expected in the first half of 2026. Initial promising data from the Phase 2 CORE-008 Cohort A in high-risk BCG-naïve NMIBC was also reported in December 2025.

• Strategic Acquisition to Strengthen Manufacturing

  In July 2025, CG Oncology acquired a controlling interest in Biovire, a contract manufacturing organization that provides clinical supply of cretostimogene. This $26.8 million acquisition is expected to strengthen manufacturing supply continuity and de-risk the supply chain for future commercialization.

auto_awesomeAnalysis

CG Oncology's annual report highlights a robust financial position, significantly bolstered by recent capital raises. The company successfully executed substantial at-the-market (ATM) equity sales at a favorable price, extending its cash runway. A key positive development is the favorable verdict in the ANI Pharmaceuticals lawsuit, which removes a potential 5% royalty burden on future sales of its lead product candidate, cretostimogene. This legal clarity, combined with ongoing clinical progress and strategic manufacturing strengthening, provides a solid foundation for the company's continued development and potential commercialization efforts. Investors should monitor upcoming clinical data readouts and the BLA submission progress.